<DOC>
	<DOC>NCT03053271</DOC>
	<brief_summary>This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome. Following wash-out, all eligible subjects will undergo a 6-week open-label dose escalation with ATR-101. Subjects who continue to be eligible will then undergo a 4-week randomized withdrawal period. It is anticipated that the overall duration of the study per subject will range from approximately 14-20 weeks.</brief_summary>
	<brief_title>A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<criteria>Confirmed diagnosis of endogenous Cushing's syndrome Baseline UFC 1.3 to 10 Ã— upper limit of normal (ULN) If previous pituitary surgery, participants must be at least 6 months since surgery at the time of screening BMI between 18 and 45 kg/m2, inclusive PseudoCushing's syndrome, cyclic Cushing's syndrome or current iatrogenic Cushing's syndrome Candidates for surgical treatment of Cushing's syndrome, unless surgery is not anticipated to occur during the study Normal late night salivary cortisol or 24hr urine free cortisol Radiotherapy of the pituitary within 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Endogenous Cushing's Syndrome</keyword>
	<keyword>ATR-101</keyword>
	<keyword>CS</keyword>
</DOC>